VIDEO: NAC for mTOR inhibition — a breakthrough for lupus/SLE and autoimmune treatment
Casual overview: Thankfully, mTOR is a nice short abbreviation in place of the cumbersome common name "Mechanistic Target of Rapamycin" which is cumbersome, grammatically incorrect, and misleading in comparison to a name that would help doctors use mTOR-related information in their clinical practices with greater comfort and ease. • M—The M can represent "Mechanistic" (which is redundant because all targets are mechanisms; so mechanistic does not add anything meaningful to the conversation) or "Mammalian" (which is unnecessary in a contextualized conversation). • T—"Target" is nonspecific and biologically meaningless; however, "targets" are common in the world of pharmacology, which is for the most part the science of how to interfere with and generally block the function of biological pathways, enzymes, and receptors. • O—"Of" is a preposition and should neither be capitalized nor included in an abbreviation; this use is poor grammar. • R—Rapamycin is an immunosuppressive "drug" that was first discovered as an antibacterial product of the soil bacterium Streptomyces hygroscopicus on the island of Rapa Nui (Easter Island). Rapamycin has been officially renamed sirolimus. Of course, naming an intracellular molecule after a drug promotes the idea that this receptor exists to receive this drug, thus reinforcing the medicocentric view of healthcare. Given that mTOR is responsive to antioxidant/Reductive therapies, Resveratrol, and dietary Restriction, we can see that replacing Rapamycin with natural treatments gives us broader conceptual and therapeutic horizons. For anyone to say that these are simply "semantic" considerations would reveal a painful ignorance of the fact that we as humans largely but not exclusively think with words and that therefore linguistic structure is the easiest manner for dictating perceptions and subsequent thoughts and actions. Having said all of that, I propose here a revisioning of mTOR via a renaming of mTOR, from mammalian target of rapamycin to the more descriptive and clinically applicable Meaningful Therapeutic Opportunity for Reductive/antioxidative therapies, Resveratrol, R-lipoic acid, Restrictive diets and a few Random/Rouge interventions already proven safe and health-promoting.
